BC Extra | Jul 10, 2018
Company News

Adlai Nortye gets rights to Novartis' buparlisib

Chinese immunotherapy company Adlai Nortye Biopharma Co. Ltd. (Hangzhou, China) gained exclusive, worldwide rights to cancer candidate buparlisib (BKM120) from Novartis AG (NYSE:NVS; SIX:NOVN). Financial terms were not disclosed. Adlai Nortye has global rights to...
BC Week In Review | Jun 29, 2018
Financial News

Adlai Nortye raises $50M series B

Chinese immunotherapy company Adlai Nortye Biopharma Co. Ltd. (Hangzhou, China) raised over $50 million in a series B round led by YuanMing Capital. Matrix Partners China, DT Capital Partners and Yahui Precision Medicine Fund also...
BC Extra | Jun 26, 2018
Financial News

Adlai Nortye raises $50M in series B

Chinese immunotherapy company Adlai Nortye Biopharma Co. Ltd. (Hangzhou, China) raised over $50 million in a series B round led by YuanMing Capital. Matrix Partners China, DT Capital Partners and Yahui Precision Medicine Fund also...
BC Week In Review | Jan 26, 2018
Company News

Adlai Nortye receives rights to solid tumor candidate E7046 from Eisai

Eisai Co. Ltd. (Tokyo:4523) granted Adlai Nortye Co. Ltd. (NEEQ:870946) exclusive, worldwide rights outside of parts of Asia to develop and commercialize solid tumor candidate E7046. Specifically, the deal excludes Japan, Korea, Taiwan, Thailand, India,...
Items per page:
1 - 4 of 4